A psychiatric medication is a licensed psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental disorders. Usually prescribed in psychiatric settings, these medications are typically made of synthetic chemical compounds, although some are naturally occurring, or at least naturally derived. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization therefore lowering the cost of mental health care.
Modern psychiatric medication has advanced greatly in the past century. A number of natural remedies exist for many different psychiatric disorders. For example, many suggest that saffron is an effective alternative treatment for depression. The Reuptake Hypothesis by Julius Axelrod involves the interaction among neurotransmitters, and forms the cornerstone of the development of modern psychotropic drugs. His work allowed researchers to further advance their studies into the effects of psychiatric medication. Mental health medications were first introduced in the mid-20th century with the widespread introduction of chlorpromazine, an antipsychotic. The popularity of these drugs have skyrocketed since then, with millions prescribed annually.
Psychiatric medications are prescription medications, requiring a prescription from a physician, such as a psychiatrist, or a psychiatric nurse practitioner, PMHNP, before they can be obtained. Some U.S. states and territories, following the creation of the prescriptive authority for psychologists movement, have granted prescriptive privileges to clinical psychologists who have undergone additional specialised education and training in medical psychology. In addition to the familiar dosage in pill form, psychiatric medications are evolving into more novel methods of drug delivery. New technologies include transdermal, transmucosal, inhalation, and suppository supplements.
Psychopharmacology studies a wide range of substances with various types of psychoactive properties. The professional and commercial fields of pharmacology and psychopharmacology do not typically focus on psychedelic or recreational drugs, and so the majority of studies are conducted on psychiatric medication. While studies are conducted on all psychoactive drugs by both fields, psychopharmacology focuses on psychoactive and chemical interactions within the brain. Physicians who research psychiatric medications are psychopharmacologists, specialists in the field of psychopharmacology. Recently there have been more studies into the field of psychedelics; this is due to the fact that this class of drugs has recently been found, or at least has been admitted, to be beneficial in psychiatry.
Adverse and withdrawal effects
Psychiatric medications carry risk for adverse effects. Whitfield has referred to psychiatric medications as potential agents of trauma  The occurrence of adverse effects can potentially reduce drug compliance. Some adverse effects can be treated symptomatically by using adjunct medications such as anticholinergics (antimuscarinics). Some rebound or withdrawal adverse effects, including the possibility of a sudden or severe emergence or re-emergence of psychosis, may appear when the drugs are discontinued, or discontinued too rapidly.
There are six main groups of psychiatric medications.
- Antidepressants, which treat disparate disorders such as clinical depression, dysthymia, anxiety, eating disorders and borderline personality disorder.
- Stimulants, which treat disorders such as attention deficit hyperactivity disorder and narcolepsy, and to suppress the appetite.
- Antipsychotics, which treat psychotic disorders such as schizophrenia and psychotic symptoms occurring in the context of other disorders such as mood disorders.
- Mood stabilizers, which treat bipolar disorder and schizoaffective disorder.
- Anxiolytics, which treat anxiety disorders.
- Depressants, which are used as hypnotics, sedatives, and anesthetics.
- Psychedelics, which have a broad array of powerful acute effects and are taken under professional supervision during extended psychotherapy sessions
Antipsychotics are drugs used to treat various symptoms of psychosis, such as those caused by psychotic disorders or schizophrenia. Atypical antipsychotics are also used as mood stabilizers in the treatment of bipolar disorder, and they can augment the action of antidepressants in major depressive disorder. Antipsychotics are sometimes referred to as neuroleptic drugs and some antipsychotics are branded "major tranquilizers".
- Chlorpromazine (Thorazine)
- Haloperidol (Haldol)
- Perphenazine (Trilafon)
- Thioridazine (Melleril)
- Thiothixene (Navane)
- Flupenthixol (Fluanxol)
- Trifluoperazine (Stelazine)
- Aripiprazole (Abilify)
- Clozapine (Clozaril)
- Olanzapine (Zyprexa)
- Paliperidone (Invega)
- Quetiapine (Seroquel)
- Risperidone (Risperdal)
- Zotepine (Nipolept)
- Ziprasidone (Geodon)
Antidepressants are drugs used to treat clinical depression, and they are also often used for anxiety and other disorders. Most antidepressants will hinder the breakdown of serotonin or norepinephrine or both. A commonly used class of antidepressants are called selective serotonin reuptake inhibitors (SSRIs), which act on serotonin transporters in the brain to increase levels of serotonin in the synaptic cleft. SSRIs will often take 3–5 weeks to have a noticeable effect, as the regulation of receptors in the brain adapts. Bi-functional SSRIs are currently being researched, which will occupy the autoreceptors instead of 'throttling' serotonin . There are multiple classes of antidepressants which have different mechanisms of action Another type of antidepressant is a monoamine oxidase inhibitor, which is thought to block the action of Monoamine oxidase, an enzyme that breaks down serotonin and norepinephrine. MAOIs are not used as first-line treatment due to the risk of hypertensive crisis related to the consumption of foods containing the amino acid tyramine.
- Fluoxetine (Prozac), SSRI
- Paroxetine (Paxil, Seroxat), SSRI
- Citalopram (Celexa), SSRI
- Escitalopram (Lexapro), SSRI
- Sertraline (Zoloft), SSRI
- Duloxetine (Cymbalta), SNRI
- Venlafaxine (Effexor), SNRI
- Bupropion (Wellbutrin), NDRI
- Mirtazapine (Remeron), NaSSA
- Isocarboxazid (Marplan), MAOI
- Phenelzine (Nardil), MAOI
In 1949, the Australian John Cade discovered that lithium salts could control mania, reducing the frequency and severity of manic episodes. This introduced the now popular drug lithium carbonate to the mainstream public, as well as being the first mood stabilizer to be approved by the U.S. Food & Drug Administration. Besides lithium, several anticonvulsants and atypical antipsychotics have mood stabilizing activity. The mechanism of action of mood stabilizers is not well understood.
Common mood stabilizers:
- Lithium carbonate (Carbolith), first and typical mood stabilizer
- Carbamazepine (Tegretol), anticonvulsant and mood stabilizer
- Oxcarbazepine (Trileptal), anticonvulsant and mood stabilizer
- Valproic acid, and Valproic acid salts (Depakine, Depakote), anticonvulsant and mood stabilizer
- Lamotrigine (Lamictal), atypical anticonvulsant and mood stabilizer
- Gabapentin, atypical GABA-related anticonvulsant and mood stabilizer
- Pregabalin, atypical GABA-ergic anticonvulsant and mood stabilizer
- Topiramate, GABA-receptor related anticonvulsant and mood-stabilizer
- Olanzapine, atypical antipsychotic and mood stabilizer
Stimulants are some of the most widely prescribed drugs today . A stimulant is any drug that stimulates the central nervous system. Adderall, a collection of amphetamine salts, is one of the most prescribed pharmaceuticals in the treatment of attention-deficit hyperactivity disorder (ADHD). Stimulants can be addictive, and patients with a history of drug abuse are typically monitored closely or even barred from use and given an alternative. Discontinuing treatment without tapering the dose can cause psychological withdrawal symptoms such as anxiety and drug craving. Many stimulants are not physiologically addictive.
- Caffeine, typical methylxanthine stimulant, found in many edibles worldwide
- Methylphenidate (Ritalin, Concerta), atypical stimulant
- Dexmethylphenidate (Focalin), active D-isomer of methylphenidate
- Dextroamphetamine (Dexedrine), more active amphetamine isomer
- Dextroamphetamine & levoamphetamine (Adderall), D,L -Amphetamine salt mix
- Methamphetamine (Desoxyn), potent amphetamphetamine-based stimulant
- Modafinil (Provigil)
Anxiolytics & hypnotics
Benzodiazepines are effective as hypnotics, anxiolytics, anticonvulsants, myorelaxants and amnesics, but are generally recommended for short-term use. They have widely supplanted barbiturates because of they have less proclivity for overdose and toxicity.
Developed in the 1950s onward, they were originally thought to be non-addictive at therapeutic doses. They are now known to cause withdrawal symptoms similar to barbiturate and alcohol withdrawal, and a severe withdrawal syndrome may last for months and years in approximately 15% of users.
Common benzodiazepines and derivatives include:
- Diazepam (Valium), benzodiazepine derivative, anxiolytic
- Nitrazepam (Mogadon), benzodiazepine derivative, hypnotic
- Zolpidem (Ambien, Stilnox), an imidazopyridine, non-benzodiazepine hypnotic
- Zopiclone (Imovan), non-benzodiazepine hypnotic ("Z-drug")
- Eszopiclone (Lunesta), non-benzodiazepine hypnotic ("Z-drug")
- Zaleplon (Sonata), non-benzodiazepine hypnotic ("Z-drug")
- Chlordiazepoxide (Librium), benzodiazepine derivative, anxiolytic
- Alprazolam (Xanax), benzodiazepine derivative, anxiolytic
- Temazepam (Restoril), benzodiazepine derivative
- Clonazepam (Klonopin), benzodiazepine derivative
- Lorazepam (Ativan), benzodiazepine derivative, anxiolytic
||This section needs more medical references for verification or relies too heavily on primary sources, specifically: Section heavily reliant on self-published report by an advocacy group and small clinical trials performed with dubious blinding by this same group. (June 2014)|
Psychedelic drugs were used in psychotherapy prior to their criminalization in the late 20th century for a wide variety of psychiatric indications. In contrast to other psychiatric medications which are taken by the patient regularly or as-needed, in psychedelic therapy, patients remain in an extended psychotherapy session during the acute activity of the drug and spend the night at the facility. In the sessions with the drug, therapists are nondirective and support the patient in exploring their inner experience. Patients participate in psychotherapy before the drug psychotherapy sessions to prepare them and after the drug psychotherapy to help them integrate their experiences with the drug.
The research of the pre-criminalization era was generally of poor quality by contemporary standards of scientific methodology. However, legal clinical research has recently resumed with more rigorous methods. MDMA psychotherapy for posttraumatic stress disorder is currently being researched in efforts to develop MDMA into a legal prescription drug. Studies have been conducted in Spain, Switzerland, and the United States and show promising results, although sample sizes in these early studies have been small. More studies of MDMA psychotherapy for PTSD are currently underway in the United States, Israel, and Canada. The first clinical study of LSD since it was criminalized was published in 2014 and showed promising results for treating end-of-life anxiety.
- T.L. Brink. (2008) Psychology: A Student Friendly Approach. "Unit 11: Clinical Psychology." pp. 226 
- Hall-Flavin, Daniel. "Natural Remedies for Depression". Mayo Clinic. Retrieved 6 May 2013.
- "The Julius Axelrod Papers". National Library of Medicine. Retrieved 6 May 2013.
- Martin, Emily; Rhodes, Lorna A. "Resources on the History of Psychiatry". National Library of Medicine. Retrieved 6 May 2013.
- Murray, Bridget (October 2003). "A Brief History of RxP". APA Monitor. Retrieved 4/11/2007.
- DeVane, C. Lindsay. "New Methods for the Administration of Psychiatric Medicine". Medscape. Retrieved 6 May 2013.
- Whitfield, Charles (2010). "Psychiatric drugs as agents of Trauma". The International Journal of Risk and Safety in Medicine 22 (4): 195–207. Retrieved 5 December 2012.
- Moncrieff, Joanna (23 March 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica (John Wiley & Sons A/S) 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. ISSN 1600-0447. PMID 16774655. Retrieved 3 May 2009.
- Schatzberg, A.F. (2000). "New indications for antidepressants". Journal of Clinical Psychiatry 61 (11): 9–17. PMID 10926050.
- Stahl, S. M. (2008). Stahl's Essential Psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press.
- "Tardive dyskinesia".
- "Monoamine Oxidase Inhibitors".
- Stephen M. Stahl, M.D., Ph.D.; et al. (2004). A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor (pdf). Journal of Clinical Psychiatry; 6(04) 159-166 2004 PHYSICIANS POSTGRADUATE PRESS, INC. Retrieved 2006-09-02.
- Ashton, Heather (July 1994). "Guidelines for the rational use of benzodiazepines. When and what to use". Drugs 48 (1): 25–40. doi:10.2165/00003495-199448010-00004. PMID 7525193. Retrieved 5 December 2012.
- MacKinnon GL, Parker WA (1982). "Benzodiazepine withdrawal syndrome: a literature review and evaluation". Am J Drug Alcohol Abuse 9 (1): 19–33. doi:10.3109/00952998209002608. PMID 6133446.
- Ashton, Heather (1991). "Protracted withdrawal syndromes from benzodiazepines". J Subst Abuse Treat. 8 (1–2): 19–28. doi:10.1016/0740-5472(91)90023-4. PMID 1675688. Retrieved 5 December 2012.
- "A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder". Multidisciplinary Association for Psychedelic Studies. 4 January 2013. Retrieved 31 May 2014.
- White, C. Michael (16 April 2014). "3,4-Methylenedioxymethamphetamine's (MDMA's) Impact on Posttraumatic Stress Disorder". Annals of Pharmacotherapy.
- De Kleine RA, Rothbaum OB, Van Minnen A. (17 Oct 2014). "Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review". Eur J Psychotraumatology 4. doi:10.3402/ejpt.v4i0.21626. PMC 3800126. PMID 24147208.
- "Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD". ClinicalTrials.gov. US National Institutes of Health. 20 March 2014. Retrieved 31 May 2014.
- "Additional MDMA-assisted Psychotherapy for People Who Relapsed After MDMA-assisted Psychotherapy Trial". ClinicalTrials.gov. US National Institutes of Health. 23 October 2013. Retrieved 31 May 2014.
- "Randomized Placebo-Controlled Study of MDMA-Assisted Psychotherapy in People With PTSD – Israel". ClinicalTrials.gov. US National Institutes of Health. February 2009. Retrieved June 17, 2009.
- "Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD". ClinicalTrials.gov. US National Institutes of Health. 1 April 2014. Retrieved 31 May 2014.
- Carey B (3 March 2014). "LSD, Reconsidered for Therapy". New York Times. Retrieved 31 May 2014.
- Children and Psychiatric Medication - a multimodal presentation
- Psychiatric Drugs: Antidepressant, Antipsychotic, Antianxiety, Antimanic Agent, Stimulant Prescription Drugs